ArticleRMD open2024

Impact of the time of initiation and line of biologic therapy on the retention rate of secukinumab in axial spondyloarthritis (axSpA): data from the French multicentre retrospective FORSYA study.

Maxime Dougados et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.